CCEL (Cryo-Cell International) Growth Rank: 1 (As of Aug. 19, 2026) — 50% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CCEL Cryo-Cell International Inc CCEL
59 GF Score
Price $4.07
GF Value $5.44
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Cryo-Cell International Growth Rank?

Cryo-Cell International CCEL +3.56% 59 Growth Rank is 1 as of Aug. 19, 2026, which is 50% below its 10-year median of 2.00. GuruFocus rates CCEL with a GF Score™ of 59/100 and a GF Value™ of $5.44 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Cryo-Cell International has the Growth Rank of 1.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Cryo-Cell International Growth Rank Related Terms

CCEL vs EHSI, PIII, CCM: Growth Rank Comparison

For the Medical Care Facilities subindustry, Cryo-Cell International's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cryo-Cell International Growth Rank vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's Growth Rank distribution charts can be found below:

* The bar in red indicates where Cryo-Cell International's Growth Rank falls into.


CCEL
59GF Score
Cryo-Cell International Inc CCEL
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 1 mean?
Cryo-Cell International (CCEL) has a Growth Rank of 1 as of Aug. 19, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Cryo-Cell International and its competitors. This is 50% below median its historical median of 2.00. Over the past decade, Cryo-Cell International's Growth Rank has ranged from 1.00 to 9.00.
Is Cryo-Cell International's Growth Rank too high?
Cryo-Cell International's current Growth Rank of 1 is 50% below median its 10-year median of 2.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 9.00. Overall, Cryo-Cell International has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cryo-Cell International's Growth Rank compare to EHSI and PIII?
Cryo-Cell International's Growth Rank of 1 can be compared against companies in the Healthcare Providers & Services industry. Historically, Cryo-Cell International's own Growth Rank has ranged from 1.00 to 9.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Healthcare Providers & Services company?
A good Growth Rank depends on the Healthcare Providers & Services industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Cryo-Cell International and its competitors. Cryo-Cell International's current Growth Rank is 1, which is 50% below median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryo-Cell International stock overvalued right now?
Based on GuruFocus' analysis, Cryo-Cell International (CCEL) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.44, compared to a current price of $4.07 — trading 25.2% below its estimated fair value. The current Growth Rank is 1, which is 50% below median its 10-year median of 2.00. Cryo-Cell International's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Cryo-Cell International (CCEL), the current Growth Rank is 1 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cryo-Cell International (CCEL) Overvalued in 2026?

Based on GuruFocus' analysis, Cryo-Cell International stock appears to be undervalued. The current stock price of $4.07 is trading 25.2% below its estimated GF Value™ of $5.44. GuruFocus considers Cryo-Cell International to be Modestly Undervalued.

Key valuation signals for CCEL:

  • Growth Rank: 1 (50% below median its 10-year median of 2.00)
  • GF Value™: $5.44 vs. price of $4.07 (25.2% below fair value)
  • GF Score™: 59/100 with 4 warning signs

No single metric tells the full story. See the CCEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cryo-Cell International Business Description

Other Exchanges ZCY:Germany
Address 700 Brooker Creek Boulevard, Suite 1800, Oldsmar, FL, USA, 34677
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
59GF Score

Get the complete analysis for CCEL

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.07
Price
$5.44
GF Value